文献速递乳腺癌放疗

放疗诱导淋巴细胞减少预测乳腺癌不良预后:保乳术后大分割放疗随机对照试验事后分析

Radiation-Induced Lymphopenia Predicts Poorer Prognosis in Patients With Breast Cancer: A Post Hoc Analysis of a Randomized Controlled Trial of Postmastectomy Hypofractionated Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-03-05

该研究对598例乳腺癌患者随机对照试验数据进行事后分析,比较保乳术后大分割放疗(HFRT)与常规分割放疗(CFRT)对外周淋巴细胞计数的影响。结果显示HFRT组淋巴细胞减少发生率显著更低,且最低点淋巴细胞计数/基线比值<0.8者5年无病生存率显著更差。

核心结论

  • 乳腺癌患者接受HFRT时放疗诱导淋巴细胞减少的风险低于CFRT。
  • 最低点外周淋巴细胞计数与基线比值偏低可能预测不良预后。

研究设计与样本

  • 对598例乳腺癌患者随机对照试验数据进行事后分析,比较保乳术后大分割放疗(HFRT,43.5 Gy/15次/3周)与常规分割放疗(CFRT,50 Gy/25次/5周)。
  • 采用t检验比较两组不同时间点平均外周淋巴细胞计数,Kaplan-Meier法和log-rank检验分析无病生存与总生存。

主要发现

  • 放疗期间两组淋巴细胞计数持续下降,放疗后1个月开始恢复。

临床怎么用

  • 保乳术后放疗选择HFRT可能降低淋巴细胞减少风险。
  • 监测外周淋巴细胞计数最低点与基线比值有助于识别预后较差患者。

局限性

  • 本研究为随机对照试验的事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to determine whether radiation-induced lymphopenia affects the survival of patients with breast cancer. METHODS AND MATERIALS: Post hoc analysis was conducted on data from 598 patients with breast cancer from a randomized controlled trial comparing postmastectomy hypofractionated radiation therapy (HFRT; 43.5 Gy in 15 fractions over 3 weeks) with conventional fractionated radiation therapy (CFRT; 50 Gy in 25 fractions over 5 weeks). Mean peripheral lymphocyte count (PLC) at different time points in the 2 groups was compared by the t test. Disease-free survival and overall survival were analyzed by the Kaplan-Meier method and compared between groups by the log-rank test. RESULTS: Baseline PLC (pre-PLC) was comparable between HFRT and CFRT patients (1.60 ± 0.57 × 109/L vs 1.56 ± 0.52 × 109/L; P = .33). In both groups, the PLC declined steadily during the course of radiation therapy but started to recover at 1 month after radiation therapy. Incidence of lymphopenia was significantly lower in HFRT patients (45.4% vs 55.7%; P = .01). Nadir-PLC was significantly higher in HFRT patients (1.08 ± 0.37 × 109/L vs 0.97 ± 0.31× 109/L; P < .001), as was the nadir-PLC/pre-PLC ratio (0.72 ± 0.28 vs 0.67 ± 0.28; P = .02). Median follow-up was 57.6 months (interquartile range, 38.5-81.4). The 5-year disease-free survival was significantly lower in patients with a nadir-PLC/pre-PLC ratio <0.8 than in those with a ratio ≥0.8 (71.8% vs 82.6%; P = .01); however, overall survival was comparable between the groups (85.8% vs 90.6%; P = .24). CONCLUSIONS: The risk of radiation-induced lymphopenia in patients with breast cancer is lower with HFRT than with CFRT. A low nadir-PLC/pre-PLC ratio may predict poor prognosis.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Sun GY, Wang SL, Song YW, et al. Radiation-Induced Lymphopenia Predicts Poorer Prognosis in Patients With Breast Cancer: A Post Hoc Analysis of a Randomized Controlled Trial of Postmastectomy Hypofractionated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020. PMID: 32147519. doi:10.1016/j.ijrobp.2020.02.633

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。